Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

Study Overview
=================
Brief Summary
-----------------
Primary Objective: - To study effect of mild and moderate hepatic impairment on the pharmacokinetics of otamixaban. Secondary Objective: - To assess the pharmacodynamic effects of otamixaban on subjects with mild and moderate hepatic impairment and in matched subjects with normal hepatic function.

Detailed Description
-----------------
The duration of each part of the study for one subject was 28 days of screening, 1 day of treatment, with 5 days in the unit (Day -1 to Day 4) and a 8 to 11 days of follow-up after start of infusion.

Official Title
-----------------
An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 μg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function.

Conditions
-----------------
Hepatic Impairment

Intervention / Treatment
-----------------
* Drug: otamixaban XRP0673


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - Subjects with hepatic impairment: Body weight between 50.0 kg and 115.0 kg inclusive if male, between 40.0 kg and 100.0 kg inclusive if female, Body Mass Index between 18.0 and 34.9 kg/m2 inclusive Stable chronic liver disease assessed by medical history, physical examination, laboratory values Vital signs, cardiac function and laboratory parameters within the acceptable range for subjects with hepatic impairment If female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal Patients with hepatic impairment will be matched to healthy subjects who are defined as healthy by physical examination, medical history and laboratory findings and are matched to patients with respect to age, gender, and body weight. Inclusion/exclusion criteria for healthy subjects may differ slightly from those listed for patients and are defined in the study protocol Exclusion criteria: Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness Creatinine level above the upper limit of normal Hepatocarcinoma Acute hepatitis Hepatic encephalopathy grade 2, 3 and 4 History or presence of drug or alcohol abuse within two years before inclusion Smoking more than 15 cigarettes or equivalent per day, unable to refrain from smoking during the institutionalization Any significant change in chronic treatment medication within 14 days before inclusion The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mild impairment<br>Patients with mild hepatic impairment | Drug: otamixaban XRP0673<br>* Pharmaceutical form: solution for injection Route of administration: intravenous<br>|
| Experimental: Moderate impairment<br>Patients with moderate impairment | Drug: otamixaban XRP0673<br>* Pharmaceutical form: solution for injection Route of administration: intravenous<br>|
| Experimental: Healthy subjects<br>Matched healthy subjects | Drug: otamixaban XRP0673<br>* Pharmaceutical form: solution for injection Route of administration: intravenous<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PK parameters including Ceoi, AUClast, AUC, C1min, CL, Vss, and t1/2z |  | Day 1 to Day 4 | 
| Pharmacodynamic based on coagulation parameters, activated partial prothrombin time (aPTT), prothrombin time (PT), and international normalized ratio (INR) |  | Screening (-28 days) up to 4 days after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety based on treatment-emergent adverse events, clinical laboratory evaluations, vital signs, and ECG |  | Screening (-28 days) up 8 to 11 days after treament |